Tolerance is the achievable 'Holy Grail' in transplantation

Current Opinion in Organ Transplantation

Volumn 11, Issue 1, 2006, Pages 24-29

  Yuan, Xueli ^a   Ansari, Mohammed Javeed ^a   Sayegh, Mohamed H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Costimulation; Regulation; T cell; Tolerance; Transplantation

Indexed keywords

BELATACEPT; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; B LYMPHOCYTE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CHIMERA; CLINICAL TRIAL; GENE THERAPY; HUMAN; KIDNEY DISEASE; NATURAL KILLER CELL; NONHUMAN; ORGAN TRANSPLANTATION; REVIEW; SIGNAL TRANSDUCTION; T CELL DEPLETION;

EID: 33644627727     PISSN: 10872418     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mot.0000203880.02687.18     Document Type: Review

References (70)

1. Sayegh MH, Carpenter CB. Transplantation 50 years later: progress, challenges, and promises. N Engl J Med 2004; 351:2761-2766. In celebrating the 50th anniversary of the first successful clinical organ transplantation procedure, this report summarizes the progress made in the past 50 years, and analyzes the challenges we are facing and promises for the future.
2. Sayegh MH, Perico N, Remuzzi G. Transplantation tolerance. A complex scenario awaiting clinical applicability. Contrib Nephrol 2005; 146:95-104. This important review summarizes the molecular and cellular basis of transplant rejection and the challenges of making transplantation tolerance a clinical reality in a general way.
3. Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation: how much of the promise has been realized? Nat Med 2005; 11:605-613. This review summarizes the methods developed to induce transplant tolerance, as a means to improve graft outcomes, eliminate the requirement for immunosuppression, and expand the pool of organs for transplantation - major challenges in the field.
4. Waldmann H, Hale G. CAMPATH: from concept to clinic. Philos Trans R Soc Lond B Biol Sci 2005; 360:1707-1711. The most up-to-date outcomes with Campath-1H (alemtuzumab), a potent lymphocyte depleting antibody, in clinical tests are summarized in this important review. This drug is thought to have the potential to facilitate tolerance and to minimize use of immunosuppressive drugs in transplantation.
5. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005; 200:505-515; quiz A59-A61. This paper shows that pretreatment with Campath-1H followed by spaced weaning of tacrolimus was more effective than thymoglobulin in clinical renal transplantation. This regimen allowed minimal immunosuppression, and a small but significant proportion of recipients were free from maintenance immunosuppression and exhibited donor specific hyporesponsiveness.
6. Neujahr D, Turka LA. Lymphocyte depletion as a barrier to immunological tolerance. Contrib Nephrol 2005; 146:65-72. This important review revisits the immunological process of homeostatic proliferation, and defines it as a barrier to tolerance in protocols that use T cell depletion by promoting the development of memory T cells.
7. + regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J Immunol 2004; 172:6003-6010.
8. Bisikirska B, Colgan J, Luban J, et al. TCR stimulation with modified anti-CD3 mAb expands CD8 T cell population and induces CD8CD25 Tregs. J Clin Invest 2005; 115:2904-2913.
9. Clarkson MR, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation 2005; 80:555-563. T cell costimulatory pathways and their roles in allograft rejection and tolerance are systemically reviewed.
10. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353:770-781. This important article analyzes the latest outcomes with belatacept, an investigational selective costimulation blocker, in clinical kidney transplantation, and indicates that belatacept preserved glomerular filtration rate better than did cylosporine and may reduce the rate of chronic allograft nephropathy.
11. Yuan X, Salama AD, Dong V, et al. The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo. J Immunol 2003; 170:2949-2955.
12. Demirci G, Amanullah F, Kewalaramani R, et al. Critical role of OX40 in CD28 and CD154-independent rejection. J Immunol 2004; 172:1691-1698. This report identifies OX40 as a critical alternative costimulatory molecule in CD28/CD154-independent rejection using a CD28/CD154 double knockout mouse model.
13. + T-cell-mediated allograft rejection. Am J Transplant 2005; 5:31-39.
14. Kashizuka H, Sho M, Nomi T, et al. Role of the ICOS-B7h costimulatory pathway in the pathophysiology of chronic allograft rejection. Transplantation 2005; 79:1045-1050.
15. Lee J, Lee EN, Kim EY, et al. 4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies. Transplant Proc 2005; 37:123-125.
16. + cytotoxic T cell responses in vivo. J Immunol 2004; 172:6039-6046.
17. + T cell mediated alloimmune responses.
18. Li W, Zheng XX, Kuhr CS, Perkins JD. CTLA4 engagement is required for induction of murine liver transplant spontaneous tolerance. Am J Transplant 2005; 5:978-986.
19. Chandraker A, Huurman V, Hallett K, et al. CTLA-4 is important in maintaining long-term survival of cardiac allografts. Transplantation 2005; 79:897-903.
20. Sandner SE, Clarkson MR, Salama AD, et al. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol 2005; 174:3408-3415. This paper describes the PD1-PDL1/PDL2 pathway, another negative pathway additional to the CTLA4 pathway, and its role in regulating alloimmune responses.
21. Gao W, Demirci G, Strom TB, Li XC. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival. Transplantation 2003; 76:994-999.
22. Sanchez-Fueyo A, Tian J, Picarella D, et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 2003; 4:1093-1101.
23. Gershon RK, Kondo K. Infectious immunological tolerance. Immunology 1971; 21:903-914.
24. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000; 101:455-458.
25. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6:345-352. This timely review summarizes the role of naturally occurring regulatory cells in tolerance.
26. reg cells and explores the possibility of and approaches to clinical application.
27. + cells, and the alloreactive T cell clone size. J Immunol 2002; 169:3744-3751.
28. + T cells on the fate of allografts in the absence of immunosuppression. Transplantation 2005; 79:648-654.
29. + regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005; 106:2903-2911.
30. reg cell therapy.
31. reg cell differentiation program.
32. + T reg homeostasis through dendritic cell-produced IL-2. Eur J Immunol 2005; 35:557-567.
33. + T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 2005; 105:2845-2851.
34. - T cells are the effector cells in disease pathogenesis in the scurfy (sf) mouse. J Immunol 1994; 153:3764-3774.
35. Bennett CL, Brunkow ME, Ramsdell F, et al. A rare polyadenylation signal mutation of the FOXP3 gene (AAUAAA→AAUGAA) leads to the IPEX syndrome. Immunogenetics 2001; 53:435-439.
36. + regulatory T cells. Nat Immunol 2003; 4:330-336.
37. reg cell development is described in this important report.
38. + regulatory T cells. Int Immunol 2004; 16:1643-1656.
39. reg cells for application in clinical transplantation.
40. Sykes M, Shimizu I, Kawahara T. Mixed hematopoietic chimerism for the simultaneous induction of T and B cell tolerance. Transplantation 2005; 79 (suppl):S28-S29.
41. Domenig C, Sanchez-Fueyo A, Kurtz J, et al. Roles of deletion and regulation in creating mixed chimerism and allograft tolerance using a nonlymphoablative irradiation-free protocol. J Immunol 2005; 175:51-60. The authors investigated the mechanisms involved in the tolerance induction by mixed chimerism and found that both deletion and regulation are important.
42. Cosimi AB, Sachs DH. Mixed chimerism and transplantation tolerance. Transplantation 2004; 77:943-946. This article reviews tolerance induction by establishment of mixed hematopoietic chimerism in animal models and humans transplant patients.
43. Tian C, Bagley J, Kaye J, Iacomini J. Induction of T cell tolerance to a protein expressed in the cytoplasm through retroviral-mediated gene transfer. J Gene Med 2003; 5:359-365.
44. Tian C, Bagley J, Forman D, Iacomini J. Induction of central tolerance by mature T cells. J Immunol 2004; 173:7217-7222. This paper reports interesting data on tolerance induction by gene transduction of donor MHC genes into mature recipient T cells, so-called induction of gene chimerism.
45. Forman D, Tian C, Iacomini J. Induction of donor-specific tolerance in sublethally irradiated recipients by gene therapy. Mol Ther 2005; 12:353-359.
46. Askenasy N, Yolcu ES, Wang Z, Shirwan H. Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection. Circulation 2003; 107:1525-1531.
47. - T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance. Transplantation 2005; 79:1310-1316.
48. Albert MH, Liu Y, Anasetti C, Yu XZ. Antigen-dependent suppression of alloresponses by Foxp3-induced regulatory T cells in transplantation. Eur J Immunol 2005; 35:2598-2607.
49. Chen W. The role of plasmacytoid dendritic cells in immunity and tolerance. Curr Opin Organ Transplant 2005; 10:181-185. This review summarizes the role played by DCs in immunity and tolerance.
50. Morelli AE, Hackstein H, Thomson AW. Potential of tolerogenic dendritic cells for transplantation. Semin Immunol 2001; 13:323-335.
51. Beriou G, Peche H, Guillonneau C, et al. Donor-specific allograft tolerance by administration of recipient-derived immature dendritic cells and suboptimal immunosuppression. Transplantation 2005; 79:969-972.
52. Khoury SJ, Gallon L, Verburg RR, et al. Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol 1996; 157:3700-3705.
53. Mirenda V, Berton I, Read J, et al. Modified dendritic cells coexpressing self and allogeneic major histocompatability complex molecules: an efficient way to induce indirect pathway regulation. J Am Soc Nephrol 2004; 15:987-997.
54. Womer KL, Sayegh MH. Donor antigen and transplant tolerance strategies: it takes two to tango! J Am Soc Nephrol 2004; 15:1101-1103.
55. Raimondi G, Thomson AW. Dendritic cells,tolerance and therapy of organ allograft rejection. Contrib Nephrol 2005; 146:105-120. This is a timely review summarizing the importance of DCs in tolerance induction and the possibility of DC therapy in organ allograft rejection.
56. Wood KJ. Is B cell tolerance essential for transplantation tolerance? Transplantation 2005; 79 (suppl):S40-S42. The importance of B cell tolerance to transplantation tolerance is discussed in this important review.
57. Tyden G, Kumlien G, Genberg H, et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5:145-148.
58. Usuda M, Fujimori K, Koyamada N, et al. Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation. Transplantation 2005; 79:12-16.
59. Agarwal A, Vieira CA, Book BK, et al. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant 2004; 4:1357-1360.
60. Fujii S. Application of natural killer T-cells to posttransplantation immunotherapy. Int J Hematol 2005; 81:1-5.
61. Yu L, Van Y, Li S, et al. Induction and maintenance of T-dependent or T-independent xenotolerance by nonprimarily-vascularized skin or thymus grafts. Transplantation 2005; 79:520-527.
62. Westerhuis G, Maas WG, Willemze R, et al. Long-term mixed chimerism after immunologic conditioning and MHC-mismatched stem-cell transplantation is dependent on NK-cell tolerance. Blood 2005; 106:2215-2220. The importance of NK cell tolerance in induction of stable mixed chimerism by MHC-mismatched hematopoietic cells is described in this paper.
63. Uehara S, Chase CM, Kitchens WH, et al. NK cells can trigger allograft vasculopathy: the role of hybrid resistance in solid organ allografts. J Immunol 2005; 175:3424-3430.
64. Beilke JN, Kuhl NR, Van Kaer L. Gill RG. NK cells promote islet allograft tolerance via a perforin-dependent mechanism. Nat Med 2005; 11:1059-1065.
65. Derks RA, Burlingham WJ. In vitro parameters of donor-antigen-specific tolerance. Curr Opin Immunol 2005; 17:560-564. Summarized in this important review are the in-vitro parameters for donor specific transplantation tolerance.
66. Tryphonopoulos P, Tzakis AG, Weppler D, et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant 2005; 5:608-613.
67. Sanchez-Fueyo A, Strom TB. Immunological tolerance and liver transplantation. J Hepatol 2004; 41:698-705. Mechanisms of transplantation tolerance are summarized in this important review, which places emphasis on liver transplantation.
68. Strober S, Lowsky RJ, Shizuru JA, et al. Approaches to transplantation tolerance in humans. Transplantation 2004; 77:932-936.
69. Tinckam KJ, Sayegh MH. Transplantation tolerance in pediatric recipients: lessons and challenges. Pediatr Transplant 2005; 9:17-27. The newest developments in transplantation tolerance are broadly reviewed in this article.
70. + T cells, and HA-1 microchimerism, in allograft tolerance. J Exp Med 2004; 199:1017-1023.